Antithrombotic Therapy after Ablation for Atrial Fibrillation
New England Journal of Medicine · 07.05.2026 · 394 (18) · 1868-1872
DOI: 10.1056/nejmc2602513 ↗Kurz gefasst
Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 07.05.2026. Verfasst von Simon Christie und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of British Columbia, Vancouver, BC, Canada. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
To the Editor: In the recent OCEAN (Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation) trial involving patients who had undergone successful catheter ablation for atrial fibrillation, Verma et al. (Jan. 22 issue) 1 report that the incidence of the primary trial outcome (a composite of stroke, systemic embolism, or new covert embolic stroke) was not significantly lower among those treated with reduced-dose rivaroxaban (15 mg per day) than among those treated with aspirin. Generalizing the results of this trial to the patient population with atrial fibrillation may be challenging because the mean CHA 2 DS 2 -VASc score (scores range from . . .
Autor:innen und Institutionen
- University of British Columbia, Vancouver, BC, Canada.
Zitieren
APA
Christie, S., & Sullivan, A. P. (2026). Antithrombotic Therapy after Ablation for Atrial Fibrillation. New England Journal of Medicine, 394(18), 1868-1872. https://doi.org/10.1056/nejmc2602513
Vancouver
Christie S, Sullivan AP. Antithrombotic Therapy after Ablation for Atrial Fibrillation. New England Journal of Medicine. 2026;394(18):1868-1872. doi:10.1056/nejmc2602513
BibTeX
@article{Christie2026,
author = {Christie, Simon and Sullivan, Andrew P},
title = {Antithrombotic Therapy after Ablation for Atrial Fibrillation},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {18},
pages = {1868--1872},
doi = {10.1056/nejmc2602513}
}
EUVIMED